SEATTLE -- Parathyroidectomy helped reverse disrupted levels of inflammatory cytokines and vitamin D metabolites in patients with primary hyperparathyroidism (PHPT), a researcher suggested here. After ...
Secondary hyperparathyroidism is a complex endocrine condition characterized by excess circulating parathyroid hormone (PTH) resulting from an underlying condition, most commonly chronic kidney ...
Several promising therapies for hypoparathyroidism (hypoPT) are currently in development, including most prominently a novel, long-acting parathyroid hormone (PTH) analog (eneboparatide) and the ...
ORLANDO, Fla. — After 2 years of treatment with the parathyroid hormone (PTH) analog palopegteriparatide (Yorvipath), adults with chronic hypoparathyroidism demonstrated continued improvement in renal ...
The US Food and Drug Administration (FDA) has approved palopegteriparatide (Yorvipath) for the treatment of hypoparathyroidism in adults, the drug's manufacturer Ascendis Pharma announced. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results